DPP4 and type 2 diabetes mellitus: DPP-4 inhibitors added to standard care may reduce mortality compared with sulfonylureas added to standard care in older type 2 diabetes patients with inadequate glycaemic control.38,40,44,45 DPP-4 inhibitors probably reduce hypoglycaemia compared with sulfonylureas, but the magnitude of the reduction cannot be reliably quantified because of heterogeneity in effect sizes between studies.38,40,43, –45 DPP-4 inhibitors have no impact on overall adverse events38,40,44,45 but may reduce discontinuation due to adverse events38,40,44,45 slightly.